Sonoma Pharmaceuticals, Inc. SNOA

Company Overview

Sonoma Pharmaceuticals, Inc. is a U.S.-based specialty healthcare company focused on developing and commercializing stabilized hypochlorous acid (HOCl) products for wound care, dermatology, eye care, oral care, animal health, and infection prevention applications. The company operates within the biotechnology, medical device, and specialty pharmaceutical industries, with products marketed for both prescription and over-the-counter use. Sonoma’s core technology platform is based on its patented Microcyn® technology, which is designed to produce stabilized HOCl solutions intended to reduce microbial contamination and support tissue care without relying on traditional antibiotics.

The company’s primary revenue drivers include sales of advanced wound care products, dermatology therapies, and licensing or distribution agreements with international commercial partners. Sonoma serves healthcare providers, hospitals, consumers, and veterinary markets across multiple geographies. The company traces its origins to Oculus Innovative Sciences, founded in 1999, and later rebranded as Sonoma Pharmaceuticals to reflect its broader healthcare commercialization strategy. Its positioning centers on non-antibiotic anti-infective technologies and diversified global distribution relationships.